Podbit · Huberman Lab
About 40 to 50% of OCD cases have a genetic component, as revealed by twin studies examining identical and fraternal twins. But genes aren't destiny — a substantial portion of OCD arises without any identifiable inherited factor.
Where this was said
At 6:55 · chapter starts 6:40
Huberman explores the hereditary dimension of OCD through the lens of twin studies — comparing identical twins (including monocorionic pairs sharing the same gestational sac), fraternal twins, and non-twin populations. The broad conclusion: approximately 40 to 50% of OCD cases have some identifiable genetic component. Huberman acknowledges this is interesting but tempers expectations about its clinical utility — people can't choose their genes or their parents. What this data does usefully establish is that OCD is not purely a product of upbringing or environment; biology loads the gun for about half of sufferers. For the other half, the disorder appears to arise through other pathways, underscoring the importance of neurological and behavioral mechanisms as intervention targets.
Twin studies suggest that roughly 40 to 50% of OCD cases have an identifiable genetic component, though genes cannot be controlled.
Dozens to hundreds of neuroimaging studies point to the cortico-striatal-thalamic loop as the primary neural circuit generating obsessions and compulsions in OCD.
Dozens to hundreds of neuroimaging studies converge on one circuit: the cortico-striatal-thalamic loop. The cortex processes perception, the striatum governs go/no-go action, and the thalamus gates what reaches consciousness. When this loop misfires, intrusive thoughts and compulsive behaviors emerge.
Social norms compress behavior so effectively that we assume other minds are similar to ours. They almost never are. After running over 100 psychology studies, Greenberg's biggest finding is that humans are far more different from each other than we intuitively believe.
The widely shared claim that we have a credit card's worth of plastic in our brains may be a massive overestimate. Researchers used nitrile gloves to measure microplastics — and nitrile gloves shed microplastic particles onto the measuring device. A second paper found the original tool used was unreliable, and that we may have far less plastic than reported.
RSD isn't just hurt feelings — it's a dopamine-deficient brain with a hyperactive amygdala and a frayed connection to the prefrontal cortex. Add a surge of norepinephrine and you get chest pain, sweating, and trembling that convinces your body something catastrophic is happening.
In Dan Ariely's door experiment, participants sacrificed the highest-reward door — repeatedly — just to avoid seeing other doors disappear. Even when researchers trained them to use the best door, they kept wasting clicks to maintain options. This is the bias that runs our lives: we'll take a worse outcome to preserve the feeling of optionality.
Dan Gilbert discovered that the brain has a 'psychological immune system' — it misremembers, reframes, and rationalizes to keep you satisfied with whatever you chose. The fear before commitment is all about potential regret. But after committing, your brain quietly starts justifying the choice — and the more irreversible the decision, the stronger the effect.
The psychological immune system can get you through the first few months of any commitment. But durable, long-term well-being requires self-concordance — choosing commitments that are genuinely aligned with your values and what you actually want. Without that alignment, the satisfaction fades fast.
Vision didn't just help animals find food — it ignited the Cambrian explosion of speciation. Half of the human cortex is devoted to visual processing, and that same visual hierarchy directly inspired the neural network architectures powering today's AI.
Peptides come loaded with a powerful narrative: regenerative, subcutaneous, targeted, cutting-edge. That narrative can genuinely move outcomes, especially for pain, energy, and recovery. The RCT's job is to quantify how much additional benefit comes from the molecule itself — above and beyond the compelling story surrounding it.
A pharmaceutical is not an amino acid sequence — it is the successful solution to manufacturing, purification, formulation, and consistency challenges. When clinical trials prove a drug works, they validate a specific product under specific processes, not every preparation that shares the same sequence.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.